Biochemistry (Moscow)

, Volume 72, Issue 3, pp 320–327 | Cite as

Mechanism of estrogen-induced apoptosis in breast cancer cells: Role of the NF-κB signaling pathway

  • Yu. S. Lobanova
  • A. M. Scherbakov
  • V. A. Shatskaya
  • M. A. Krasil’nikovEmail author


The ability of sex steroid hormones to up-regulate the apoptotic signaling proteins is well documented; however, the apoptotic potential of sex hormones is not remarkable and fully compensated by their growth stimulatory action to target cells. In the present study using the long-term cultivation of estrogen-dependent MCF-7 breast cancer cells in steroid-free medium, we have established a cell subline, designed as MCF-7/LS, which was characterized by the resistance to growth stimulatory estradiol action and hypersensitivity to estrogen-induced apoptosis. We have demonstrated that estrogen treatment of the cells does not influence on the level of TNF-R1 or Fas, but dramatically decreases the transcriptional activity of NF-κB. Importantly, the MCF-7/LS cells, which are insensitive to growth stimulatory estrogen action, retain the ability to decrease in the NF-κB activity in response to estrogen stimulus. Furthermore, the significant increase in the basal (in the absence of ligand) estrogen receptor (ER)-dependent transcriptional activity in the MCF-7/LS cells was revealed and reciprocal transcriptional antagonism between ER and NF-κB was demonstrated. Finally, we proved the possible involvement of phosphatidylinositol-3 kinase (PI3K) in the ligand-independent ER activation. In general, the results presented suggest that long-term growth of MCF-7 breast cancer cells in steroid-free medium is accompanied with the increase in the basal ER-dependent transcriptional activity as well as the maintenance of the negative regulatory loop ER-NF-κB. The latter may be considered as one of the factors resulting in a disbalance between pro-and anti-apoptotic pathways and enhancement in estrogen apoptotic action in the cells.

Key words

breast cancer apoptosis estrogens NF-κB phosphatidylinositol-3 kinase 



estrogen receptor


estrogen responsive element


3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide


propidium iodide


phosphatidylinositol-3 kinase


phosphatase dephosphorylating 3-OH-phosphoinositides


tumor necrosis factor α


type I tumor necrosis factor receptor


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Krasil’nikov, M. A. (2004) Vopr. Onkol., 50, 399–405.PubMedGoogle Scholar
  2. 2.
    Bershtein, L. M., and Santen, R. (2002) Vopr. Onkol., 48, 17–23.Google Scholar
  3. 3.
    Normanno, N., di Maio, M., de Maio, E., de Luca, A., de Matteis, A., Giordano, A., and Perrone, F. (2005) Endocr. Relat. Cancer, 12, 721–747.PubMedCrossRefGoogle Scholar
  4. 4.
    Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O’Brien, K., Wang, Y., and Hilakivi-Clarke, L. A. (2003) Oncogene, 22, 7316–7339.PubMedCrossRefGoogle Scholar
  5. 5.
    Jordan, V. C. (2003) Ann. Oncol., 14, 969–970.PubMedCrossRefGoogle Scholar
  6. 6.
    Beekman, J. M., Allan, G. F., Tsai, S. Y., Tsai, M. J., and O’Malley, B. W. (1993) Mol. Endocrinol., 7, 1266–1274.PubMedCrossRefGoogle Scholar
  7. 7.
    Leclercq, G., Lacroix, M., Laios, I., and Laurent, G. (2006) Curr. Cancer Drug Targets, 6, 39–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Marino, M., Acconcia, F., and Ascenzi, P. (2005) Curr. Drug Targets Immune Endocr. Metab. Disord., 5, 305–314.CrossRefGoogle Scholar
  9. 9.
    Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., and Nakshatri, H. (2001) J. Biol. Chem., 276, 9817–9824.PubMedCrossRefGoogle Scholar
  10. 10.
    Rollerova, E., and Urbancikova, M. (2000) Endocr. Regul., 34, 203–218.PubMedGoogle Scholar
  11. 11.
    Ring, A., and Dowsett, M. (2004) Endocr. Relat. Cancer, 11, 643–658.PubMedCrossRefGoogle Scholar
  12. 12.
    Stoica, G. E., Franke, T. F., Wellstein, A., Czubayko, F., List, H. J., Reiter, R., Morgan, E., Martin, M. B., and Stoica, A. (2003) Mol. Endocrinol., 17, 818–830.PubMedCrossRefGoogle Scholar
  13. 13.
    Song, R. X., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J., and Santen, R. J. (2001) J. Natl. Cancer Inst., 93, 1714–1723.PubMedCrossRefGoogle Scholar
  14. 14.
    Song, R. X., and Santen, R. J. (2003) Apoptosis, 8, 55–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Song, R. X., Zhang, Z., Mor, G., and Santen, R. J. (2005) Apoptosis, 10, 667–678.PubMedCrossRefGoogle Scholar
  16. 16.
    Liu, H., Lee, E. S., Gajdos, C., Pearce, S. T., Chen, B., Osipo, C., Loweth, J., McKian, K., De Los Reyes, A., Wing, L., and Jordan, V. C. (2003) J. Natl. Cancer Inst., 95, 1586–1597.PubMedGoogle Scholar
  17. 17.
    Osipo, C., Gajdos, C., Liu, H., Chen, B., and Jordan, V. C. (2003) J. Natl. Cancer Inst., 95, 1597–1608.PubMedGoogle Scholar
  18. 18.
    Shcherbakov, A. M., Lobanova, Yu. S., Shatskaya, V. A., Onopchenko, O. V., Gasparian, A. V., Gershtein, E. S., and Krasil’nikov, M. A. (2006) Byul. Eksp. Biol. Med., 141, 334–337.CrossRefGoogle Scholar
  19. 19.
    Lewis, J. S., Osipo, C., Meeke, K., and Jordan, V. C. (2005) J. Steroid Biochem. Mol. Biol., 94, 131–141.PubMedCrossRefGoogle Scholar
  20. 20.
    Osipo, C., Gajdos, C., Cheng, D., and Jordan, V. C. (2005) J. Steroid Biochem. Mol. Biol., 93, 249–256.PubMedCrossRefGoogle Scholar
  21. 21.
    Lonning, P. E., Taylor, P. D., Anker, G., Iddon, J., Wie, L., Jorgensen, L. M., Mella, O., and Howell, A. (2001) Breast Cancer Res. Treat., 67, 111–116.PubMedCrossRefGoogle Scholar
  22. 22.
    Peethambaram, P. P., Ingle, J. N., Suman, V. J., Hartmann, L. C., and Loprinzi, C. L. (1999) Breast Cancer Res. Treat., 54, 117–122.PubMedCrossRefGoogle Scholar
  23. 23.
    Jordan, V. C., Osipo, C., Schafer, J. M., Fox, J. E., Cheng, D., and Liu, H. (2003) Breast, 12, 432–441.PubMedCrossRefGoogle Scholar
  24. 24.
    Osipo, C., Liu, H., Meeke, K., and Jordan, V. C. (2004) Exp. Biol. Med. (Maywood), 229, 722–731.Google Scholar
  25. 25.
    Okumura, N., Saji, S., Eguchi, H., Hayashi, S., Saji, S., and Nakashima, S. (2002) Jap. J. Cancer Res., 93, 867–873.Google Scholar
  26. 26.
    Saji, S., Nakashima, S., Hayashi, S., Toi, M., Saji, S., and Nozawa, Y. (1999) Jap. J. Cancer Res., 90, 210–218.Google Scholar
  27. 27.
    Mor, G., Kohen, F., Garcia-Velasco, J., Nilsen, J., Brown, W., Song, J., and Naftolin, F. (2000) J. Steroid Biochem. Mol. Biol., 73, 185–194.PubMedCrossRefGoogle Scholar
  28. 28.
    Lewis, J. S., Meeke, K., Osipo, C., Ross, E. A., Kidawi, N., Li, T., Bell, E., Chandel, N. S., and Jordan, V. C. (2005) J. Natl. Cancer Inst., 97, 1746–1759.PubMedCrossRefGoogle Scholar
  29. 29.
    Provost, P. R., Blomquist, C. H., Godin, C., Huang, X. F., Flamand, N., Luu-The, V., Nadeau, D., and Tremblay, Y. (2000) Endocrinology, 141, 2786–2794.PubMedCrossRefGoogle Scholar
  30. 30.
    Krasil’nikov, M. A., Shatskaya, V. A., Stavrovskaya, A. A., Erohina, M., Gershtein, E. S., and Adler, V. V. (1999) Biochim. Biophys. Acta, 1450, 434–443.PubMedCrossRefGoogle Scholar
  31. 31.
    Olea-Serrano, N., Devleeschouwer, N., Leclercq, G., and Heuson, J. C. (1985) Eur. J. Cancer Clin. Oncol., 21, 965–973.PubMedCrossRefGoogle Scholar
  32. 32.
    Reid, G., Hubner, M. R., Metivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J., and Gannon, F. (2003) Mol. Cell, 11, 695–707.PubMedCrossRefGoogle Scholar
  33. 33.
    Gasparian, A. V., Yao, Y. J., Kowalczyk, D., Lyakh, L. A., Karseladze, A., Slaga, T. J., and Budunova, I. V. (2002) J. Cell Sci., 115, 141–151.PubMedGoogle Scholar
  34. 34.
    Tolkacheva, T., and Chan, A. M. (2000) Oncogene, 19, 680–689.PubMedCrossRefGoogle Scholar
  35. 35.
    Hotz, M. A., Gong, J., Traganos, F., and Darzynkiewicz, Z. (1994) Cytometry, 15, 237–244.PubMedCrossRefGoogle Scholar
  36. 36.
    Danforth, D. N., and Zhu, Y. (2005) Breast Cancer Res. Treat., 94, 81–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Galea, E., Santizo, R., Feinstein, D. L., Adamsom, P., Greenwood, J., Koenig, H. M., and Pelligrino, D. A. (2002) Neuroreport, 13, 1469–1472.PubMedCrossRefGoogle Scholar
  38. 38.
    Biswas, D. K., Singh, S., Shi, Q., Pardee, A. B., and Iglehart, J. D. (2005) Sci. STKE, 288, 27–32.Google Scholar
  39. 39.
    Kalaitzidis, D., and Gilmore, T. D. (2005) Trends Endocrinol. Metab., 16, 46–52.PubMedCrossRefGoogle Scholar
  40. 40.
    Pratt, M. A., Bishop, T. E., White, D., Yasvinski, G., Menard, M., Niu, M. Y., and Clarke, R. (2003) Mol. Cell. Biol., 23, 6887–6900.PubMedCrossRefGoogle Scholar
  41. 41.
    Stoica, G. E., Franke, T. F., Moroni, M., Mueller, S., Morgan, E., Iann, M. C., Winder, A. D., Reiter, R., Wellstein, A., Martin, M. B., and Stoica, A. (2003) Oncogene, 22, 7998–8011.PubMedCrossRefGoogle Scholar
  42. 42.
    Vilgelm, A., Lian, Z., Wang, H., Beauparlant, S. L., Klein-Szanto, A., Ellenson, L. H., and di Cristofano, A. (2006) Cancer Res., 66, 3375–3380.PubMedCrossRefGoogle Scholar
  43. 43.
    Aquila, S., Sisci, D., Gentile, M., Middea, E., Catalano, S., Carpino, A., Rago, V., and Ando, S. (2004) J. Clin. Endocrinol. Metab., 89, 1443–1451.PubMedCrossRefGoogle Scholar
  44. 44.
    Evans, M. J., Eckert, A., Lai, K., Adelman, S. J., and Harnish, D. C. (2001) Circ. Res., 89, 823–830.PubMedGoogle Scholar
  45. 45.
    McKay, L. I., and Cidlowski, J. A. (1999) Endocr. Rev., 20, 435–459.PubMedCrossRefGoogle Scholar
  46. 46.
    Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Cell Death Differ., 10, 45–65.PubMedCrossRefGoogle Scholar
  47. 47.
    Ariazi, E. A., and Jordan, V. C. (2006) Curr. Top. Med. Chem., 6, 203–215.PubMedGoogle Scholar
  48. 48.
    Zhou, W., Liu, Z., Wu, J., Liu, J. H., Hyder, S. M., Antoniou, E., and Lubahn, D. B. (2006) J. Clin. Endocrinol. Metab., 91, 569–579.PubMedCrossRefGoogle Scholar
  49. 49.
    Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. (2000) Cancer Res., 60, 5887–5894.PubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2007

Authors and Affiliations

  • Yu. S. Lobanova
    • 1
  • A. M. Scherbakov
    • 2
  • V. A. Shatskaya
    • 1
  • M. A. Krasil’nikov
    • 1
    Email author
  1. 1.Institute of Carcinogenesis, Blokhin Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia
  2. 2.Institute of Clinical Oncology, Blokhin Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations